Fisher & Paykel Healthcare Corporation Ltd
ASX:FPH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
29.22
34.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fisher & Paykel Healthcare Corporation Ltd
Nestled in the heart of New Zealand, Fisher & Paykel Healthcare Corporation Ltd. has emerged as a formidable player in the global healthcare market, largely due to its innovative spirit and relentless focus on respiratory care solutions. Originally part of Fisher & Paykel Industries, the healthcare division carved its own path in 2001, quickly becoming synonymous with high-quality medical devices. The company’s journey can be compared to a constant rhythm of innovation, particularly in areas that address obstructive sleep apnea, acute respiratory distress, and surgical humidification. Its revenue streams are primarily bolstered by a diverse array of products, including sleep apnea masks, humidifier systems for intensive care units, and related respiratory accessories. These offerings are not just technological marvels but are designed to improve patient outcomes and their quality of life, which resonates well with healthcare providers worldwide.
Over the years, Fisher & Paykel Healthcare has strategically expanded its operations beyond its Kiwi roots, anchoring its presence in over 120 countries. This global footprint, coupled with a robust pipeline of patented products, enables sustained revenue growth and stability. The company’s financial health is driven by a business model that emphasizes research and development, ensuring that it remains at the forefront of medical innovation. By fostering close relationships with healthcare professionals and institutions, Fisher & Paykel not only gains invaluable insights to refine its products but also cultivates a loyal customer base. This enduring approach cements its position not only as a leader in the healthcare sector but also as a trusted partner in the critical mission to enhance patient care worldwide.
Nestled in the heart of New Zealand, Fisher & Paykel Healthcare Corporation Ltd. has emerged as a formidable player in the global healthcare market, largely due to its innovative spirit and relentless focus on respiratory care solutions. Originally part of Fisher & Paykel Industries, the healthcare division carved its own path in 2001, quickly becoming synonymous with high-quality medical devices. The company’s journey can be compared to a constant rhythm of innovation, particularly in areas that address obstructive sleep apnea, acute respiratory distress, and surgical humidification. Its revenue streams are primarily bolstered by a diverse array of products, including sleep apnea masks, humidifier systems for intensive care units, and related respiratory accessories. These offerings are not just technological marvels but are designed to improve patient outcomes and their quality of life, which resonates well with healthcare providers worldwide.
Over the years, Fisher & Paykel Healthcare has strategically expanded its operations beyond its Kiwi roots, anchoring its presence in over 120 countries. This global footprint, coupled with a robust pipeline of patented products, enables sustained revenue growth and stability. The company’s financial health is driven by a business model that emphasizes research and development, ensuring that it remains at the forefront of medical innovation. By fostering close relationships with healthcare professionals and institutions, Fisher & Paykel not only gains invaluable insights to refine its products but also cultivates a loyal customer base. This enduring approach cements its position not only as a leader in the healthcare sector but also as a trusted partner in the critical mission to enhance patient care worldwide.
Revenue Growth: Second half revenue rose 14% to $890.5 million, signaling a return to more normal market conditions post-COVID.
Flat Profit: Net profit after tax for the half was $154.4 million, flat year-on-year.
Gross Margin Pressures: Full-year gross margin fell to 59.4%, mainly due to elevated freight costs and manufacturing inefficiencies, but improved in the second half.
Strong Homecare: Homecare revenue jumped 25% in the second half, with mask sales particularly robust following a successful Evora Full mask launch.
Guidance Issued: FY2024 revenue guidance is approximately $1.7 billion, with gross margin expected to improve by about 200 basis points in constant currency.
Margins Target: Management reiterated a plan to return to a 65% gross margin within 3–4 years and an operating margin of 30%.
Dividend Raised: The full-year dividend increased 3% to $0.405 per share.
Operating Expenses: OpEx is expected to grow 12% in FY2024, reflecting the full-year cost of new hires made in 2023.
